NEW YORK (GenomeWeb) – Thermo Fisher Scientific and French firm Cellectis have inked a series of agreements covering the use of TAL nucleases for a variety of applications.

Under the agreements, Thermo Fisher gains a worldwide license under Cellectis' IP rights to use TAL nucleases outside the therapeutics field with exclusive rights to grant sublicenses in research and development, bioproduction, and applied markets. Thermo Fisher's Life Technologies business markets TAL nucleases under the brand name TALEN for these applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.